Analytical Data
-
Gene name
MICB
- Application
-
Alternative Names
MHC class I polypeptide-related sequence B; MIC-B; PERB11.2
-
Species
Human
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
NP_005922.2
-
Expression Region
A23-T308
-
Molecular Weight
45-55 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MICB (MHC class I polypeptide-related sequence B) is a key protein involved in the immune response, primarily recognized for its role in the activation of natural killer (NK) cells. As a member of the MHC class I gene family, MICB is expressed in response to cellular stress, infection, or transformation, thereby serving as a signal for immune surveillance. The protein binds to the NKG2D receptor on NK cells and certain T cells, leading to their activation and subsequent elimination of stressed or malignant cells. In recent years, the study of recombinant MICB proteins has garnered significant attention due to their potential applications in immunotherapy, particularly in cancer treatment. By developing and using recombinant MICB proteins, researchers aim to enhance the binding affinity to NKG2D receptors, thereby improving the efficacy of NK cell-mediated cytotoxicity. Moreover, understanding the structural and functional properties of recombinant MICB can provide insights into its interactions with other immune components, paving the way for novel therapeutic strategies. Advances in recombinant DNA technology and protein engineering have enabled the production of MICB in heterologous systems, allowing for detailed studies on its functional mechanisms and interactions within the immune system. As a result, MICB is not only a critical player in innate immunity but also holds promise as a target for innovative cancer therapies. The increasing body of research focused on recombinant MICB proteins underscores the importance of this molecule in shaping future approaches to immunomodulation and cancer treatment.
